HS-10241
Sponsors
Atridia Pty Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions
Advanced CancerAdvanced Non-small Cell Lung CancerCarcinomaNeoplasmNon Small Cell Lung CancerSolid TumorSolid Tumor, AdultSolid Tumors
Phase 1
A Phase I Trial of HS-10241 in Solid Tumors
CompletedNCT02759640
Start: 2016-09-30End: 2018-05-31Updated: 2022-07-20
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
NCT02977364
Start: 2016-11-30End: 2021-11-30Target: 50Updated: 2016-11-30
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
NCT03243643
Start: 2017-08-08End: 2019-12-31Target: 80Updated: 2017-09-08
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
NCT04477057
Start: 2019-06-21End: 2021-12-31Target: 30Updated: 2020-07-20
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT05430386
Start: 2022-01-05End: 2023-12-31Target: 174Updated: 2023-02-14
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
Not yet recruitingNCT06823245
Start: 2025-02-28End: 2025-07-31Target: 32Updated: 2025-02-12